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Abstract
Background: Polycythemia vera (PV), characterized by massive production of erythrocytes, is one of the
myeloproliferative neoplasms. Most patients carry a somatic gain-of-function mutation in JAK2, c.1849G > T
(p.Val617Phe), leading to constitutive activation of JAK-STAT signaling pathway. Familial clustering is also observed
occasionally, but high-penetrance predisposition genes to PV have remained unidentified.
Results: We studied the predisposition to PV by exome sequencing (three cases) in a Finnish PV family with four
patients. The 12 shared variants (maximum allowed minor allele frequency <0.001 in Finnish population in ExAC
database) predicted damaging in silico and absent in an additional control set of over 500 Finns were further
validated by Sanger sequencing in a fourth affected family member. Three novel predisposition candidate
variants were identified: c.1254C > G (p.Phe418Leu) in ZXDC, c.1931C > G (p.Pro644Arg) in ATN1, and c.701G > A
(p.Arg234Gln) in LRRC3. We also observed a rare, predicted benign germline variant c.2912C > G (p.Ala971Gly) in
BCORL1 in all four patients. Somatic mutations in BCORL1 have been reported in myeloid malignancies. We further
screened the variants in eight PV patients in six other Finnish families, but no other carriers were found.
Conclusions: Exome sequencing provides a powerful tool for the identification of novel variants, and
understanding the familial predisposition of diseases. This is the first report on Finnish familial PV cases, and we
identified three novel candidate variants that may predispose to the disease.
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Background
Myeloproliferative neoplasms (MPNs) are a group of
hematological malignancies with enhanced proliferation
of myeloid cells due to an acquired mutation of a single
hematopoietic stem cell (HSC) resulting in clonal
progeny [1, 2]. Expansion of red blood cells in the
peripheral blood and bone marrow is the hallmark of
polycythemia vera (PV). PV is a chronic, Philadelphia
chromosome-negative myeloproliferative disorder with
symptoms including fatigue, pruritus, and splenomegaly.
The patients have an increased risk of thrombosis, and
the disease may further progress to secondary acute
myeloid leukemia (sAML) or myelofibrosis [3].
The global annual incidence rate of PV is approxi-
mately 1 per 100,000 persons [4]. Most PV patients
(approximately 95%) carry a somatic mutation in exon
14 of a non-receptor tyrosine kinase-coding gene Janus
kinase 2 (JAK2), c.1849G > T (p.Val617Phe, subsequently
referred to as JAK2V617F) [5–8]. The major diagnostic
criteria for PV according to World Health Organization
(2008) are exceptionally high hemoglobin and presence
of JAK2V617F mutation. Other criteria include consist-
ent bone marrow morphology and low erythropoietin
(Epo) levels [9, 10]. When diagnosed with PV, most pa-
tients are older than 60 years old, and survival depends
on the complications and severity of the disease. In
younger patients, life expectancy is reduced when com-
pared to the general population [11].
Janus kinase 2 (JAK2) plays a crucial role in the function
and maintenance of HSCs [12], as well as in myelopoiesis
through binding to various cytokine receptors including
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erythropoietin receptor (Epo-R), thus, contributing to for-
mation of red blood cells [13]. V617F mutation, which is
located within the pseudokinase domain of JAK2
protein, leads to constitutive activity that promotes
cytokine hypersensitivity and abnormal signaling
through Janus kinase-signal transducer and activator of
transcription factor (JAK-STAT) pathway [5–8]. In
addition, approximately 3% of PV patients, being
JAK2V617F-negative, harbor mutations in exon 12 of
JAK2. The mutations in both exons 14 and 12 induce
cytokine-independent proliferation of cells expressing Epo-
receptors [14]. Also, certain germline mutations in JAK2
are predicted to represent a mechanism possibly preceding
the acquisition of JAK2V617F mutation in PV [15].
Although most PV cases appear to be sporadic, familial
clustering is also observed in a subset of cases [16–18].
JAK2V617F-positive MPNs are strongly associated with
JAK2 46/1, or ‘GGCC’ haplotype (rs10974944), which is
a common, moderate penetrance predisposition allele
[19–22]. Also, a single nucleotide polymorphism (SNP)
in the telomerase reverse transcriptase gene (TERT),
rs2736100, has emerged as another predisposing factor
to MPNs [23]. In addition, it has been shown that germline
duplication of ATG2B and GSKIP genes predisposes to
familial myeloid malignancies [24], and germline RBBP6
mutations have been associated with familial MPNs [25]. It
is likely that additional inherited genetic factors contribute
to PV development as well, since familial clustering of PV
suggests the presence of additional susceptibility alleles.
High-penetrance predisposition genes to PV have, however,
remained unidentified.
Here, we report a Finnish family with four PV patients
in two generations (Additional file 1: Figure S1). A family
with this many cases is quite exceptional, since PV is a
rare disease and usually sporadic. Also, in a familial PV
case like here, the age at diagnosis is usually lower, which
is an additional indication of the presence of predisposing
factors. DNA from all the PV patients in this family was
available. The aim of this study was to identify new predis-
posing gene variants by exome sequencing the DNA of
three of the affected family members; the index case and
two affected family members (germline) and peripheral
blood DNA of the index case. Exome sequencing was not
feasible in the fourth PV patient due to very low amount
of archived DNA available. The observed, predicted as
damaging, germline variants were analyzed in the fourth
PV patient of the family, and the variants shared by all
four individuals were further screened in six other families
with two PV cases in each.
Methods
Patient samples
We investigated a Finnish family with four PV patients
(Additional file 1: Figure S1). The index case (1.1) was
diagnosed with PV at the age of 36, and with myelofibrosis
later at the age of 47. The father (1.2) of the index patient
was diagnosed with PV at the age of 48, and the aunt (1.9)
with PV and acute leukemia at the age of 91. The uncle
(1.10) of the index patient was diagnosed with PV at the
age of 83. Two individuals in the family had lymphoma;
1.19 was diagnosed with nodular lymphocyte-predominant
Hodgkin lymphoma (NLPHL) at the age of 55, and with
diffuse large cell non-Hodgkin lymphoma (NHL) later at
the age of 68; 1.6 was diagnosed with differentiated diffuse
lymphocytic lymphoma at the age of 89. The healthy
daughter of the index case is currently 31 years old.
Both peripheral blood and buccal swab samples were
available from the index case. Only formalin-fixed paraf-
fin embedded (FFPE) blocks were available from three
other family members diagnosed with PV: 1.2, 1.9, and
1.10. Germline DNA was also available from one of two
lymphoma patients (1.19) of the family. The second
sample set consisted of FFPE blocks from six other
Finnish PV families with two first-degree relative cases
in five, and two more distant relatives in the sixth family.
The study was approved by the appropriate Ethics
Review Committee. Samples were derived either after a
signed informed consent or after authorization from the
National Supervisory Authority for Welfare and Health.
The study was conducted in accordance with the
Declaration of Helsinki.
Exome capture and sequencing
DNA was extracted from FFPE blocks with a standard
phenol-chloroform method, and the buccal swab sample
was extracted with QIAmp DNA Mini kit (Qiagen,
Hilden, Germany). DNA from the blood sample was
extracted with a standard non-enzymatic TKM buffer-
proteinase K method. Sample libraries of gDNA were
prepared using NEBNext DNA Library Prep Reagent Set
for Illumina (New England Biolabs Ltd. Catalog #
E6000), and exomic regions were enriched using Agilent
Sure SelectXT Human All Exon V4 + UTRs 50Mb kit
(Agilent Technologies, Santa Clara, CA, USA). Paired-
end short read sequencing was performed with HiSeq
2000 (Illumina Inc., San Diego, CA, USA) at Karolinska
Institutet, Sweden. The DNA library for whole-genome
sequencing was prepared with KAPA Hyper Prep Kit
(KAPA Biosystems, Wilmington, MA, USA). Paired-end
short read sequencing was performed with HiSeq 4000
(Illumina Inc.) at Karolinska Institutet.
Variant analysis
Exome and genome sequencing data was mapped against
the human reference genome GRCh37 (1000 Genomes
Project reference hs37d5) with Burrow-Wheeler Aligner
(BWA MEM, v.0.7.12, https://arxiv.org/abs/1303.3997),
and mapped reads refined following the Genome Analysis
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Toolkit (GATK) Best Practices workflow including PCR
duplicate removal, indel realignment, and base quality
score recalibration [26]. Single-nucleotide and short-indel
variants were then called using GATK HaplotypeCaller.
The SNV and indel variants in the exome sequencing
data were analyzed with an in-house developed analysis
and visualization tool (BasePlayer, Katainen et al., manu-
script in preparation). A minimum coverage of four
reads and the mutated allele present in at least 20% of
the reads was required to call a variant. The variants
which were present in an in-house control set of 542
Finns [93 whole genome sequenced individuals from the
1000 Genomes Project, 402 whole-genome sequenced
individuals from Kuusamo, Finland (Sequencing Initia-
tive Suomi), and 47 uterine leiomyoma patients] were
excluded. To exclude common variants, we further fil-
tered the variant set against the Exome Aggregation
Consortium (ExAC v.0.3: 3,307 Finns) data [27], setting
the maximum allowed minor allele frequency (MAF) in
Finnish population to 0.001. Germline variants predicted
benign by two independent computational methods
PolyPhen-2 [28] and SIFT [29] were excluded.
Direct sequencing
The shared variants found in the exome data and
BCORL1 cDNA were validated by direct Sanger se-
quencing. Also, the predisposing germline variant
rs10974944 in JAK2 was checked. DNA was extracted
from FFPE blocks with a standard phenol-chloroform
method or with NucleoSpin® DNA FFPE XS kit
(Macherey-Nagel, Düren, Germany). Primers were de-
signed using Primer3Plus software (http://www.bioinfor
matics.nl/primer3plus). The DreamTaq™ DNA Polymerase
(Thermo Scientific, Waltham, MA, USA) or Invitrogen™,
Platinum™, SuperFi™ DNA Polymerase (Thermo Scientific)
were used in PCR reactions, and PCR products were
purified with A’SAP PCR clean-up method (ArcticZymes,
Tromsø, Norway). BigDye Terminator v3.1 sequencing
reaction was used in the DNA sequencing, and capillary
electrophoresis was performed on an ABI3730xl DNA
Analyzer (Applied Biosystems, Foster City, CA, USA) at
the Institute for Molecular Medicine Finland (FIMM).
The results were analyzed manually using FinchTV v.1.4.0
(Geospiza Inc., Seattle, WA, USA).
For cDNA sequencing, RNA was extracted from index
case’s whole blood sample with NucleoSpin® RNA kit
(Macherey-Nagel), and reverse-transcripted to cDNA
with Promega M-MLV Reverse Transcriptase (Thermo
Scientific) according to manufacturers’ protocols.
Results and discussion
Novel candidate germline variants for PV predisposition
Here, we have studied a Finnish family with four PV
cases with the aim of identifying novel PV-predisposing
germline variants. Germline DNA exomes from three
affected family members and the peripheral blood DNA
exome of the index case were sequenced. The average
coverage at each base was 58 reads and 88% of the cap-
tured regions had a minimum coverage of four reads.
We filtered the called variants based on their predicted,
damaging effect on the gene product, and their presence
in an in-house control set of 542 Finns. We removed the
variants that occurred in any of the 542 Finnish controls
(MAF < 0.2%, 95% Cl [0, 0.05%]), leaving us with 12
shared variants; 1 splice site and 11 possibly pathogenic
missense variants (Table 1). We then validated the vari-
ants by Sanger sequencing in one additional family
member diagnosed with PV (1.10).
From these variants predicted as damaging, 1.10
carried three rare single-nucleotide variants (SNVs):
c.1254C >G (p.Phe418Leu) in ZXDC (ENST00000389709);
c.1931C >G (p.Pro644Arg) in ATN1 (ENST00000356654);
Table 1 A list of damaging (in silico) germline variants in PV patients detected by exome sequencing (three cases)
Gene Ensembl gene Ensembl transcript Genomic location Variation, cDNA Variation, protein
ZXDC* ENSG00000070476 ENST00000389709 Chr3: 126189754 c.1254C > G p.Phe418Leu
ATN1* ENSG00000111676 ENST00000356654 Chr12: 7046361 c.1931C > G p.Pro644Arg
LRRC3* ENSG00000160233 ENST00000291592 Chr21: 45877228 c.701G > A, rs148872771 p.Arg234Gln
GNL3 ENSG00000163938 ENST00000418458 Chr3: 52727477 c.1241A > G p.Tyr414Cys
MDC1 ENSG00000137337 ENST00000376406 Chr6: 30679188 c.2221-1G > T splice site variant
ITPR3 ENSG00000096433 ENST00000374316 Chr6: 33635026 c.1672C > T, rs780906252 p.Arg558Cys
FAM135A ENSG00000082269 ENST00000418814 Chr6: 71190668 c.607G > A, rs143901584 p.Val203Met
SLC2A12 ENSG00000146411 ENST00000275230 Chr6: 134312391 c.1756C > T, rs200847615 p.Pro586Ser
WDR86 ENSG00000187260 ENST00000334493 Chr7: 151097265 c.226G > A, rs199824863 p.Asp76Asn
CSMD1 ENSG00000183117 ENST00000537824 Chr8: 3165238 c.3929C > T p.Ala1310Val
SLC24A2 ENSG00000155886 ENST00000341998 Chr9: 19786283 c.582A > G, rs368590535 p.Ile194Met
ITPKC ENSG00000086544 ENST00000263370 Chr19: 41224132 c.1092C > G, rs143757004 p.Asp364Glu
The three shared variants in all four cases are marked with an asterisk. Genome assembly: GRCh37
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and rs148872771, c.701G >A (p.Arg234Gln) in LRRC3
(ENST00000291592). We screened the three variants in
lymphoma patient 1.19, who carried the variant in LRRC3.
Also, we checked for the three variants in the germlines of
eight PV patients from six other Finnish families, but the
variants were not observed. It may still be possible, how-
ever, that some of the three variants or other variants in
these genes may play a role in PV development. We identi-
fied also one rare benign (PolyPhen-2, SIFT) missense SNP,
rs144332650, c.2912C >G (p.Ala971Gly), and in BCORL1
(ENST00000540052) in all four PV patients in the family.
Mutations in BCORL1 have been associated with the
leukemogenic process in AML [30–32]. PV patients in six
other families did not carry the variant.
Zinc-finger X-linked duplicated family member C
(ZXDC) belongs to the ZXD family of transcription fac-
tors, which has been observed to regulate transcription
of major histocompatibility complex (MHC) class I and
II genes in antigen presenting cells [33]. In addition to
zinc fingers, ZXDC contains a transcriptional activation
domain, and a specific domain used for interaction with
a transcriptional co-factor class II trans-activator
(CIITA), which leads to CIITA binding to promoter ele-
ments involved in constitutive MHC class II expression
[33, 34]. By reducing the expression of ZXDC, CIITA
activation of MHC class II gene transcription is signifi-
cantly reduced [33]. Thus, downregulation of ZXDC
may contribute to carcinogenesis and malignant progres-
sion of tumors by participating in the suppression of
MHC class II genes. The mutated site of ZXDC identi-
fied in our study is the first amino acid of the ninth zinc
finger repeat. Zinc fingers are necessary for full activity
of cooperation with CIITA [33]. Beyond this role of
acting as a co-factor in CIITA function, the ZXDC gene
function is unknown. ZXDC is enriched in myeloid line-
ages and has been observed to regulate transcription of
key genes during myeloid cell differentiation [35]. Dur-
ing hematopoiesis, it is expressed especially in stem and
progenitor cells in the bone marrow, myelocytes, and
leukocytes (BloodSpot http://nar.oxfordjournals.org/con
tent/early/2015/10/26/nar.gkv1101.abstract, www.protei
natlas.org). Solely based on gene function, ZXDC variant
would be the most attractive predisposition candidate of
the three, but further studies are warranted.
Atrophin-1 (ATN1) is a nuclear transcriptional core-
pressor, and aberrant form of ATN1 is associated with
neurodegenerative diseases such as dentatorubral-
pallidoluysian atrophy (DRPLA), and cancer in humans
[36]. It is ubiquitously expressed in neurons [37] and
widely in various other tissues, e.g., in hematopoietic
cells in the bone marrow (www.proteinatlas.org). ATN1
contains glutamine-repeats, and two arginine-glutamic
acid dipeptide-like repeats (RE-repeats) [36]. In neuronal
nuclei, ATN1 has been shown to interact with a
transcriptional repressor Eight twenty-one (ETO) pro-
tein [38]. In normal hematopoiesis, it is widely expressed
in differentiated blood cells, but the expression is lower
in stem and progenitor cells (BloodSpot). Thus, it is
likely that ATN1 interaction with ETO has no contribu-
tion to erythropoiesis or development of myeloprolifera-
tive diseases. On the other hand, in patients with AML,
ATN1 is expressed more substantially (BloodSpot) com-
pared to normal counterparts. Nevertheless, its normal
function is not completely understood.
Little is known about the function of Leucine-rich
repeat containing 3 (LRRC3) gene product, but it is
widely expressed in different tissues, including the bone
marrow. Most malignancies display moderate cytoplasmic-
positive staining, and the strongest expression is observed
in colorectal cancers (www.proteinatlas.org). One lymph-
oma patient of the family with DNA available carried the
rare variant rs148872771 in LRRC3, too, which may indi-
cate the particular variant not being responsible for PV
predisposition exclusively.
The SNP in JAK2, rs10974944, was identified in all the
PV patients in the family. Individuals 1.1, 1.2, and 1.10
were homozygous for the risk variant in their germline
(GG genotype), whereas 1.9 was heterozygous (CG
genotype). Also, all eight PV patients from the six other
families carried the risk variant: two of them were het-
erozygous, and six were homozygous. The SNP in TERT,
rs2736100, was also checked from the patients. All the
PV patients in the studied family were homozygous for
the risk variant (CC).
Germline duplication of ATG2B and GSKIP has been
shown to predispose to familial myeloid malignancies
[24]. A possible duplication was checked for in the
whole-genome sequence data of the index case by visual-
izing the depth of coverage in the region. The duplica-
tion had not occurred in the index patient’s genome.
Detection of somatic variants
We identified the most frequent somatic variation in PV
patients, JAK2V617F, in index case’s blood sample. Loss of
heterozygosity (LOH) in the 12 damaging gene variants
detected by exome sequencing was looked for in the index
case’s blood sample, but only the variants c.582A >G
(p.Ile194Met) in SLC24A2 and c.3929C > T (p.Ala1310Val)
in CSMD1, in addition to JAK2V617F, showed clear LOH.
In known MPN-associated genes, the index case carried
two missense variants, c.680C > T (p.Thr227Met) in FLT3
and c.5162 T >G (p.Leu1721Trp) in TET2 (Illumina Tru-
Sight® Myeloid Sequencing Panel), predicted as possibly
damaging by PolyPhen-2 and SIFT. In addition, we identi-
fied possibly damaging missense variants c.3263C > T
(p.Ser1088Phe) and c.1235C > T (p.Ala412Val) in FANCA,
which is one of the genes associated with other myeloid
malignancies [39, 40].
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BCORL1 gene is located on the X chromosome. The
index case being a woman, we checked which of the
alleles was expressed; the BCORL1 variant or the wild-
type. By Sanger sequencing the cDNA, we identified the
expression of BCORL1 variant.
Conclusions
Identification of predisposing genes and mutations is
important for families with PV susceptibility and ac-
knowledging family history is essential in order to unveil
the genetic background. New hereditary gene defects
may lead to screening and genetic counseling of family
members and may improve the diagnosis and treatment
thus affecting the quality of life. Also, the identification
of specific gene mutations gives the possibility to screen
individuals at higher risk. This is the first report on
Finnish familial PV cases, and we identified three candi-
date predisposition variants by exome-sequencing. We
would like to present these genes as candidates for PV
susceptibility and for further validation by the research
community.
Additional file
Additional file 1:Figure S1. Pedigree of the Finnish family with four
cases of polycythemia vera, and two cases of lymphoma. Exome-sequenced
family members are marked with an asterisk and the individual used for
validation with a small square. The index case was also whole-genome
sequenced (peripheral blood DNA), in addition to germline exome
sequencing. Acute leukemia is marked with a small circle. The pedigree
has been slightly modified for confidentiality. (PDF 1382 kb)
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